Alors que les populations sud africaines ont un besoin cruel de médicaments, les nouveaux médicaments ont un mal fou à pénétrer le marché du pays. Pourquoi ? Dans leur article, Urbach et Stevens, dénoncent la lourdeur de la réglementation sud africaine qui entrave lourdement la mise sur le marché de nouveaux médicaments. Les démarchent peuvent […]
This author has yet to write their bio.Meanwhile lets just say that we are proud gnadm contributed a whooping 6 entries.
Entries by gnadm
The UN High Level Report on Access to medicines threatens the nascent boom in biopharmaceutical R&D in middle-income such as India and China, according to Geneva Network, a UK-based research organisation working on international trade, health and intellectual property issues. Since China and India upgraded their protection for intellectual property in the mid 2000s, their […]
Our research on the impact of increased periods of data exclusivity in Japan and Canada on pharmaceutical spending is mentioned in this Washington Post article.
Countries need to commit to abolishing import tariffs on drugs Geneva, September 29, 2015 ─ A new study from Geneva Network has found that the global volume of trade in medicines that have their price increased by tariffs is growing at 21% per year. This means more patients in countries such as India, Brazil, Pakistan […]
What’s happened in the first six months of Geneva Network – new studies on IP, health and trade. Find out more
Geneva Network co-hosted its first event on 21 May, in Singapore, with our friends at SEANET. The aim was to cast some light over the debate about TPP and health, which so far has been rather apocalyptic. Prof Elizabeth Ng of the National University of Singapore kicked off by giving some context around the TPP, […]